Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 2, 2009, Pages

  Bin, Lianghua ^a   Howell, Michael D ^a,b   Kim, Byung Eui ^a   Hall, Clifton F ^a   Streib, Joanne E ^a   Leung, Donald Y M ^a,b  

^a DEPARTMENT OF MEDICINE   (United States)

^b Children's Hospital Colorado   (United States)

Author keywords

atopic dermatitis; IFN ; IL 10 receptor; IL 29; S100A11; vaccinia virus

Indexed keywords

2' 5' OLIGOADENYLATE SYNTHETASE; CRYSTAL VIOLET; INTERFERON RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 15; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 29; INTERLEUKIN 6 RECEPTOR; S100A11 PROTEIN; SMALL INTERFERING RNA; SYNTHETASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOWN REGULATION; EVALUATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; KERATINOCYTE; MICROARRAY ANALYSIS; ORTHOMYXOVIRUS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; STAINING; VACCINIA VIRUS; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS RESISTANCE; WESTERN BLOTTING;

EID: 67651207490     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.05.002     Document Type: Article

References (37)

1. Leung D.Y., Boguniewicz M., Howell M.D., Nomura I., and Hamid Q.A. New insights into atopic dermatitis. J Clin Invest 113 (2004) 651-657
2. Homey B., Steinhoff M., Ruzicka T., and Leung D.Y. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118 (2006) 178-189
3. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002) 1151-1160
4. Howell M.D., Gallo R.L., Boguniewicz M., Jones J.F., Wong C., Streib J.E., et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 24 (2006) 341-348
5. Howell M.D., Wollenberg A., Gallo R.L., Flaig M., Streib J.E., Wong C., et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 117 (2006) 836-841
6. Howell M.D., Fairchild H.R., Kim B.E., Bin L., Boguniewicz M., Redzic J.S., et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol 128 (2008) 2248-2258
7. Howell M.D., Jones J.F., Kisich K.O., Streib J.E., Gallo R.L., and Leung D.Y. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 172 (2004) 1763-1767
8. Kim B.E., Leung D.Y., Streib J.E., Kisich K., Boguniewicz M., Hamid Q.A., et al. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. J Allergy Clin Immunol 119 (2007) 457-463
9. Sakaguchi M., Miyazaki M., Takaishi M., Sakaguchi Y., Makino E., Kataoka N., et al. S100C/A11 is a key mediator of Ca(2+)-induced growth inhibition of human epidermal keratinocytes. J Cell Biol 163 (2003) 825-835
10. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171 (2003) 3262-3269
11. Hennings H., Holbrook K., Steinert P., and Yuspa S. Growth and differentiation of mouse epidermal cells in culture: effects of extracellular calcium. Curr Probl Dermatol 10 (1980) 3-25
12. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 (2003) 69-77
13. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4 (2003) 63-68
14. Sommereyns C., Paul S., Staeheli P., and Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4 (2008) e1000017
15. Mordstein M., Kochs G., Dumoutier L., Renauld J.C., Paludan S.R., Klucher K., et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4 (2008) e1000151
16. Robek M.D., Boyd B.S., and Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79 (2005) 3851-3854
17. Contoli M., Message S.D., Laza-Stanca V., Edwards M.R., Wark P.A., Bartlett N.W., et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12 (2006) 1023-1026
18. Meager A., Visvalingam K., Dilger P., Bryan D., and Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 31 (2005) 109-118
19. Holgate S.T. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 28 (2007) 248-251
20. Seder R.A., and Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12 (1994) 635-673
21. Stanford M.M., and McFadden G. The "supervirus"? lessons from IL-4-expressing poxviruses. Trends Immunol 26 (2005) 339-345
22. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
23. Oshikawa K., Kuroiwa K., Tago K., Iwahana H., Yanagisawa K., Ohno S., et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 164 (2001) 277-281
24. Shimizu M., Matsuda A., Yanagisawa K., Hirota T., Akahoshi M., Inomata N., et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 14 (2005) 2919-2927
25. Brint E.K., Xu D., Liu H., Dunne A., McKenzie A.N., O'Neill L.A., et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5 (2004) 373-379
26. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261 (1993) 472-475
27. Colotta F., Re F., Muzio M., Polentarutti N., Minty A., Caput D., et al. Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem 269 (1994) 12403-12406
28. Donnelly R.P., Sheikh F., Kotenko S.V., and Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 76 (2004) 314-321
29. Commins S., Steinke J.W., and Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 121 (2008) 1108-1111
30. Hor S., Pirzer H., Dumoutier L., Bauer F., Wittmann S., Sticht H., et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 279 (2004) 33343-33351
31. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14 (2008) 275-281
32. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14 (2008) 282-289
33. Dambacher J., Beigel F., Zitzmann K., Heeg M.H., Goke B., Diepolder H.M., et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 41 (2008) 209-216
34. Coccia E.M., Severa M., Giacomini E., Monneron D., Remoli M.E., Julkunen I., et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34 (2004) 796-805
35. Martinez J., Huang X., and Yang Y. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J Immunol 180 (2008) 1592-1597
36. Eckert R.L., Broome A.M., Ruse M., Robinson N., Ryan D., and Lee K. S100 proteins in the epidermis. J Invest Dermatol 123 (2004) 23-33
37. Rotz L.D., Dotson D.A., Damon I.K., and Becher J.A. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 50 (2001) 1-25